Industry evening symposium
Early prevention: protecting patients from the consequences of COPD exacerbations
AstraZeneca
Organized by : AstraZeneca
Aims : The AstraZeneca-sponsored, scientific exchange symposium will be held virtually at ERS and will convene leading experts to discuss the limitations in the current ‘step-wise’ approach to COPD management and explore the potential benefits of triple therapy in limiting symptom burden, reducing exacerbation rates, and extending patient lives. Looking to the future, experts with further examine the potential for personalising treatments through an early, biology-led approach. Interactive breakout Q&A sessions will follow the main symposium.
Chairs
F. Martinez
New York
(United States)
19:15
Welcome, introduction and opening remarks
F. Martinez (New York, United States)
1
4217
19:20
A journey through the past: the burden associated with the ‘step-wise’ approach to COPD management
J. Hurst (London, United Kingdom)
2
4218
19:35
A ‘state-of-the-art’ approach: benefits of fixed-dose combination triple therapies
F. Martinez (New York, United States)
3
4219
19:55
Looking to the future: pioneering a proactive approach to optimise management of our patients with COPD
M. Bafadhel (London, United Kingdom)
4
4220
20:07
Audience Q&A and concluding remarks
F. Martinez (New York, United States)
5
4221
20:15
Breakout: interactive Q&A session
F. Martinez (New York, United States)J. Hurst (London, United Kingdom)M. Bafadhel (London, United Kingdom)
6
4222
. . .
